Popliteal artery aneurysms treatments: early mid-term results of the use of endovascular stent grafts

Kaptanıderya TAYFUR1,* Mehmet Şenel BADEMCİ2

1Department of Cardiovascular Surgery, Faculty of Medicine, Ordu University, Ordu Training and Research Hospital, Ordu, Turkey
2Department of Cardiovascular Surgery, Faculty of Medicine, Istanbul Medeniyet University, Göztepe Training and Research Hospital, Istanbul, Turkey

Received: 21.05.2020 • Accepted/Published Online: 27.12.2020 • Final Version: 28.06.2021

Background/aim: Popliteal artery aneurysms (PAAs) are abnormal bulgings, which account for 70% of all peripheral artery aneurysms. They are usually asymptomatic. In this study, we present our long-term results of endovascular stent grafts in the treatment of PAA in the light of literature data.

Material and methods: A total of 63 legs of 63 patients with PAA, who were treated with endovascular techniques in our clinic between July 2010 and July 2019, were retrospectively analyzed. All patients underwent color Doppler ultrasound (DUS), magnetic resonance angiography (MRA), or computed tomography angiography (CTA) to identify the diameter and length of PAAs, vessel tortuosity, the presence and degree of thrombus, and diameter in the healthy landing zone and to visualize tibioperoneal vascular structures. A Viabahn stent graft was inserted in all patients.

Results: 57 patients (90.5%) were males with a mean age of 76.35 ± 7 years. 24 patients (38.1%) were symptomatic, while 11 patients (17.5%) had a concomitant abdominal aortic aneurysm (AAA). The mean follow-up period was 46.05 ± 25.01 months. The primary patency rate was 79.3%. A graft thrombosis was observed in 13 patients (20.6%) during a mean follow-up period of 8.31 ± 5.91 months. The number of distal arteries was significantly lower in the patients with thrombosis than those without.

Conclusions: Endovascular treatment of PAA using stent grafts is safe in selected cases. However, it is reasonable to avoid endovascular treatment due to an increased risk for thrombosis in patients with a low number of patent distal arteries or impaired distal flow.

Key words: Peripheral, vascular, stenting, aneurysm
include shorter operation duration, potential avoidance of general anesthesia, possibility of bilateral intervention in a single session, shorter length of hospital stay, and less perioperative mortality [8,9].

On the other hand, no consensus on endovascular treatment of PAAAs has been reached, yet. In this study, we present our long-term results of endovascular stent grafts in the treatment of PAA and to provide in the light of literature data.

2. Materials and methods

2.1. Study design and study population

This single-center, retrospective study included a total of 63 legs of 63 patients with PAA who were treated with endovascular techniques in our clinic between July 2010 and July 2019. Data including demographic and clinical characteristics and aneurysm and operative data were recorded. Asymptomatic patients with an aneurysm diameter of >20 mm were also included. The main complaints of symptomatic patients on admission include persistent knee pain, venous pressure symptoms, claudication, and bulging behind the knee joint. A written informed consent was obtained from each patient. The study protocol was approved by the local Ethics Committee. The study was conducted in accordance with the principles of the Declaration of Helsinki.

All patients underwent color DUS, MRA, or CTA to identify the diameter and length of PAAs, vessel tortuosity, the presence and degree of thrombus, and vessel diameter in the healthy landing zone to visualize tibioperoneal vascular structures (Figure 1). Patients with severe atherosclerotic occlusive disease at the level of iliac and femoral arteries, without an adequate and appropriate distal and proximal landing zone, and those with unsuitable tibioperoneal anatomy were considered ineligible for endovascular treatment and excluded.

2.2. Endovascular technique

All procedures were performed under spinal or local anesthesia in the angiography laboratory by experienced surgeons. A 7Fr or 9Fr sheath was inserted to the femoral artery through percutaneous access, while ≥10Fr sheath was reserved for surgical access. All patients received 5000 IU standard heparin after the procedure. Computed tomography angiography was performed to identify the size and location of PAA and vessel size and diameter in the healthy landing zone (Figure 2). A 0.035-inch guidewire was then inserted into the vessel lumen for stent graft implantation. A Viabahn stent graft (W.L. Gore & Associates Inc., Flagstaff, AZ, USA) was inserted in all patients (Figure 3). The diameter and length of the stent graft to be used were chosen based on precise MRA or CTA measurements preoperatively. The diameter of the graft to be used was selected as exceeding the luminal diameter by 10 to 15%. For the use of multiple stent grafts, distal stents were placed initially and proximal stents were then placed, providing an overlap by a minimum of 20 mm. After stenting, balloon dilatation was performed. Technical success was defined as the elimination of aneurysm without endoleak and with intact distal flow (Figure 4). Following the procedure, a loading dose of clopidogrel 300 mg was given to all patients, followed by 75 mg clopidogrel and 100 mg acetylsalicylic acid daily. Treatment modification was avoided in patients using oral anticoagulants for other indications. For this technique, appropriate proximal and distal stent landing zones and patent distal tibioperoneal arteries should be met. And also, increased aneurysm length is a disadvantage for endovascular repair. The diameter and length of the stents should be chosen carefully. During the postoperative follow-up period, it should be ensured that patients receive correct and sufficient antiagregant treatment.

2.3. Postoperative follow-up

All patients were followed at one, six, and 12 months for the first year and annually thereafter using CTA. During follow-up, stent graft fractures and graft thrombosis were evaluated through conventional angiography for patients.
with symptoms of thrombosis or claudication, and secondary interventions were planned. All patients were given 75mg clopidogrel and 100mg acetylsalicylic acid during the postoperative period.

2.4. Statistical analysis
Statistical analysis was performed using SPSS for Windows version 17.0 software (SPSS Inc., Chicago, IL, USA). Descriptive data were expressed in mean ± standard deviation (SD), median (interquartile range), or number and frequency. The Fisher's exact test and Chi-square test were used to analyze significant differences between variables. The Kolmogorov–Smirnov test was used to test whether the variables were normally distributed. An independent samples t-test was used to determine whether there was a statistically significant difference in normally distributed data, while the Mann–Whitney U test was carried out for nonnormally distributed data. A P value of <0.05 was considered statistically significant with 95% confidence interval (CI).

2. Results
Of all patients, 57 (90.5%) were males and six (9.5%) were females with a mean age of 76.35 ± 7.46 (range, 45 to 88) years. At the time of admission, 24 patients (38.1%) were symptomatic, while 11 patients (17.5%) had a concomitant AAA (abdominal aortic aneurysm). Baseline demographic and clinical characteristics of the patients are shown in Table 1.

The mean PAA diameter was 32.19 ± 5.98 mm. Endovascular procedure was performed under local
anesthesia in 53 patients, and access was maintained through percutaneous route in 50 patients. The mean number of stent grafts implanted was $1.55 \pm 0.64$. None of the patients had any access site-related complications. Intraoperative data are shown in Table 2.

The mean length of hospital stay was $1.92 \pm 0.72$ days. No in-hospital mortality was seen, and no stent graft thrombosis, migration, or fracture were observed within 30 days. The mean follow-up was $46.05 \pm 25.01$ months. The primary patency rate was $79.3\%$. A graft thrombosis was observed in 13 patients ($20.6\%$) during a mean follow-up of $8.31 \pm 5.91$ months. Two patients ($15.3\%)$ with graft thrombosis had stent graft fracture, while five patients ($7.9\%)$ had thrombosis due to antiplatelet therapy cessation. The patients with stent graft fracture underwent a second intervention using additional stent grafts. However, five patients with graft thrombosis in whom fibrinolysis therapy failed underwent femoropopliteal bypass. Complete patency was achieved in patients undergoing additional stent graft insertion and fibrinolysis therapy. None of the patients needed amputation; however, five patients died from several reasons and were excluded from the follow-up. The secondary patency rate was $84.12\%$. No endoleak was observed during the follow-up (Table 3).

The mean PAA diameter was significantly higher, and the mean number of tibioperoneal distal arteries was significantly lower in the patients with graft thrombosis than those without ($P < 0.05$). The mean number of distal

| Variable | n (%) |
|----------|-------|
| Male     | 57 (90.5) |
| Age, year (mean ± SD) | 76.35 ± 7.46 |
| Concomitant AAA | 11 (17.5) |
| Hypertension | 44 (69.8) |
| Smoking     | 51 (81.0) |
| Diabetes    | 9 (14.3) |
| CAD        | 18 (28.6) |
| Hyperlipidemia | 39 (61.9) |
| COPD       | 16 (25.4) |
| Symptomatic | 24 (38.1) |
| PAA diameter, mm (mean ± SD) | 32.19 ± 5.98 |
| Aneurysm length, mm (mean ± SD) | 228.97 ± 40.24 |
| Number of distal arteries/patient (mean ± SD) | 2.35 ± 0.72 |

SD: standard deviation; AAA: abdominal aortic aneurysm; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; PAA: popliteal artery aneurysm.

| Variable | N (%) |
|----------|-------|
| Percutaneous access | 50 (79.36) |
| Ipsilateral access | 58 (92.06) |
| Local anesthesia | 53 (84.12) |
| Contrast level (mean ± SD) | 47.30 ± 10.66 |
| Number of stents/patient (mean ± SD) | 1.55 ± 0.64 |
| Length of stent, cm (mean ± SD) | 9.05 ± 3.45 |
| Operation duration, min (mean ± SD) | 39.51 ± 7.44 |
| Technical success | 63 (100) |

SD: standard deviation.
arteries was 1.77 ± 0.83 and 2.50 ± 0.61 in the patients with and without graft thrombosis, respectively (P < 0.05). However, there was no significant difference in other variables between the patients with and without graft thrombosis (Table 4).

The mean PAA diameter and length and the mean number of stent grafts per patient were significantly higher in the patients with AAA than those without (P < 0.05). The mean PAA diameter was 37.98 ± 7.33 mm and 30.97 ± 4.91 mm in the patients with AAA and those without AAA, respectively (P < 0.05). In addition, the ratio of symptomatic patients with AAA was significantly higher than those without AAA (P < 0.05). All patients were intravenously hydrated using 0.9% isotonic saline after the procedure. None of the patients had acute renal insufficiency (Table 5).

When the 63 patients included in the study were analysed, 6mm stent graft was used in 30 patients, 7mm stent graft was used in 22 patients, and 8mm stent graft was used in 11 patients. In all patients, 1 mm larger balloon than stent graft was used for fixation and dilation. In the study, stent thrombosis was seen in 13 patients. In 9 of 13 patients, had 6mm stent graft and in the remaining 5 patients had 7mm stent graft with thrombosis.

3. Discussion
Popliteal artery aneurysms are the most common peripheral artery aneurysms with an estimated incidence of 0.1 to 2.8% [10]. About 80% of PAAs asymptomatic at the time of diagnosis and are often diagnosed incidentally; however,

| Variable                        | n (%)     | Without thrombosis n = 50 | With thrombosis n = 13 | P       |
|---------------------------------|-----------|---------------------------|------------------------|---------|
| Male                            |           | 45 (90.9)                 | 12 (92.3)              | 0.639a  |
| Age, year (mean ± SD)           | 77.14 ± 7.87 | 73.71 ± 4.66              | 0.099b                 |
| Abdominal aneurysm              | 8 (16.0)  | 3 (23.1)                  | 0.405a                 |
| HT                              | 34 (68.0) | 10 (76.9)                 | 0.398a                 |
| Smoking                         | 40 (80.0) | 11 (84.6)                 | 0.528a                 |
| DM                              | 7 (14.0)  | 2 (15.4)                  | 0.599a                 |
| CAD                             | 14 (28.0) | 4 (30.8)                  | 0.547a                 |
| Hyperlipidemia                  | 30 (60.0) | 9 (69.2)                  | 0.392a                 |
| COPD                            | 12 (24.0) | 4 (30.8)                  | 0.430a                 |
| Contrast level, cc (mean ± SD)  | 48.00 ± 9.90 | 44.61 ± 13.30             | 0.312a                 |
| Aneurysm diameter, mm (mean ± SD) | 20.10 ± 3.74 | 33.00 ± 6.21               | 0.007b                |
| Aneurysm length, mm (mean ± SD) | 229.65 ± 41.01 | 226.37 ± 38.59             | 0.796a                 |
| Number of distal arteries/patient [median (interquartile range)] | 3(1) | 2(1.50) | 0.003a |
| Number of stents [median (interquartile range)] | 1(1) | 2(1) | 0.122a |
| Length of stent, mm [median (interquartile range)] | 9(5) | 10(4) | 0.867a |
| Follow-up, month [median (interquartile range)] | 36(31.50) | 70(57) | 0.008b |
| Operation duration, min (mean ± SD) | 40.70 ± 7.07 | 34.92 ± 7.31               | 0.011b                |
| Length of hospital stay, day [median (interquartile range)] | 2(0.25) | 2(1) | 0.412a |

*aFisher’s exact test, bIndependent samples t-test, and ‘Mann–Whitney U test. SD: standard deviation; HT: hypertension; DM: diabetes mellitus; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease.*
asymptomatic PAAs become symptomatic at a rate of 14% per year. Symptomatic PAA may resemble acute or chronic limb ischemia, knee pain, nerve entrapment or vein pressure. In general, an aneurysm diameter of >20 mm is an indication for surgery in asymptomatic cases. Ruptured or symptomatic PAAs should be treated immediately. About 20% of asymptomatic cases are at risk for limb loss due to late complications of PAA.

In the literature, there is still no consensus on the optimal treatment of PAA. Conventional treatment includes bypass surgery using an autologous saphenous vein or synthetic graft. However, access-related complications may occur in 30 to 40% of cases, indicating a high perioperative morbidity rate. In addition, surgery is associated with postoperative complications such as major amputation, major bleeding requiring a second operation, nerve injury, deep vein thrombosis or wound site infection. Therefore, endovascular technique offers more advantages than conventional surgery in the treatment of PAA with shorter operation duration and length of hospital stay, more rapid functional recovery, minimal blood loss and wound site infection, and avoidance of general anesthesia. Endovascular treatment, however, is associated with stent graft occlusion, fracture, or migration and endoleak; thus, it is still controversial in the treatment of PAA. Popliteal artery aneurysms may be bilateral and most of them present with aneurysms of other anatomic locations. They are mostly seen in men.

In our study, 90% of the patients were males and 17.5% of the patients had a concomitant AAA. Of note, Dick Cheney, the vice president of the United States, underwent endovascular stent grafting for bilateral PAA in 2005. In the same year, Antonella et al. published the first prospective, randomized study comparing open surgery versus endovascular technique in the treatment of PAA. The authors found no statistically significant difference in the four-year patency rates and limb salvage between the two groups. Nonetheless, the authors emphasized the advantages of endovascular treatment with shorter length of hospital stay and rapid recovery. In another study, the primary and secondary patency rates were found to be 84.8% and 96.8%, respectively without

Table 5. Comparison of demographic and clinical characteristics between patients with and without abdominal aortic aneurysms.

| Parameter | Without AAA n = 52 | With AAA n = 11 | P |
|-----------|-------------------|----------------|---|
| Male      | 49 (94.2)         | 8 (72.7)       | 0.060a |
| Age, year (mean ± SD) | 75.88 ± 7.62  | 78.54 ± 6.52  | 0.286c |
| Thrombosis | 10 (19.2)        | 3 (27.3)       | 0.405a |
| HT        | 34 (65.4)         | 10 (90.9)      | 0.089a |
| Smoking   | 42 (80.8)         | 9 (81.8)       | 0.652a |
| DM        | 7 (13.5)          | 2 (18.2)       | 0.495a |
| CAD       | 12 (23.1)         | 6 (54.5)       | 0.046a |
| Hyperlipidemia | 28 (53.8) | 11 (100.0)    | 0.003a |
| COPD      | 11 (21.2)         | 5 (45.5)       | 0.100a |
| Symptomatic | 14 (26.9)      | 10 (90.9)      | 0.000a |
| Contrast level, cc (mean ± SD) | 46.83 ± 11.29  | 49.54 ± 6.87  | 0.447a |
| Aneurysm diameter, mm (mean ± SD) | 30.97 ± 4.91   | 37.98 ± 7.33  | 0.000a |
| Aneurysm length, mm (mean ± SD) | 222.05 ± 35.50 | 261.66 ± 46.75 | 0.002a |
| Number of distal arteries/patient [median (interquartile range)] | 3(1) | 2(1) | 0.222c |
| Number of stents [median (interquartile range)] | 1(1) | 2(2) | 0.046c |
| Length of stent, mm [median (interquartile range)] | 8(3) | 15(10) | 0.134c |
| Follow-up duration, month [median (interquartile range)] | 36(34.50) | 66(50) | 0.059c |
| Operation duration, min (mean ± SD) | 39.31 ± 7.14   | 40.45 ± 9.07  | 0.646a |
| Thrombosis duration, month (mean ± SD) | 8.30 ± 6.13    | 8.33 ± 6.35   | 0.994a |
| Length of hospital stay, day [median (interquartile range)] | 2(0) | 2(1) | 0.143c |

aFisher’s exact test, bIndependent samples t-test, cMann–Whitney U test, and dChi-square test (odds ratio). SD: standard deviation; AAA: abdominal aortic aneurysm; HT: hypertension; DM: diabetes mellitus; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease.
The popliteal region is constantly subjected to movement and bending which may endanger the performance and durability of the stent graft. Therefore, the stent graft to be chosen is of utmost importance. It should be very flexible and resistant. In a study, heparin-coated stent grafts yielded a significantly higher patency rate than bare metal stents in the treatment of PAA [20]. Similarly, the Viabahn stent graft is a composite based on the combination of a thin, heparin-coated polytetrafluoroethylene lining and a surrounding self-expanding nitinol stent. In our study, a Viabahn stent graft was inserted in all patients. Furthermore, a successful stent graft implantation requires appropriate proximal and distal landing zones and patent distal tibioperoneal arteries [21]. The evaluation of the distal arteries is critical to ensure the durability of the endovascular repair, since the number of patent distal arteries increases, the possibility of stent occlusion decreases. The incidence of graft thrombosis has been reported to be higher in patients with only one patent distal artery than those with two or more patent arteries [22]. In our study, the limited number of distal arteries was significantly correlated with an increased rate of graft thrombosis. The mean number of distal arteries was 1.77 ± 0.83 and 2.50 ± 0.61 in the patients with and without graft thrombosis, respectively. In a recent study, the limited number of patent distal arteries was found to be an independent risk factor for poor primary patency rates. [23]

With the introduction of reports of Tielluiu et al. [24] in 2005, the use of postprocedural antiplatelet therapy has become standard and has dramatically increased the patency rates. In our study, five patients who discontinued antiplatelet therapy within the first year developed graft thrombosis. In addition, PAAAs of <30 mm have a lower complication rates [25]. Similarly, the mean PAA diameter was significantly higher in the patients with graft thrombosis in our study. It has been also well established that increased aneurysm length is a disadvantage for endovascular repair as it requires the use of more stent grafts. In our study, although we used a higher number of stent grafts in the patients with graft thrombosis, no significant difference was found.

Review of the literature reveals limited data regarding the relationship between PAAs and AAAs. In our study, 11 patients had a concomitant AAA. The mean PAA diameter and length were significantly higher and the number of stent grafts used was significantly greater in the patients with concomitant AAAs than those without. In addition, 10 of 11 patients (90.9%) were symptomatic, which reached statistical significance.

Endovascular treatment of PAAs is associated with serious complications, such as endoleak caused by reflux of the blood into the aneurysmal sac through genicular arteries. The incidence of such endoleaks is very low in the literature [26–27]. Similarly, none of our patients had endoleak. In addition, similar to our study, the rate of stent occlusion has been estimated as low varying between 9 to 20% [18,22,28]. Graft thrombosis can be managed by a second endovascular intervention, fibrinolytic therapy, or surgical bypass. In general, stent graft thrombosis is associated with a high rate of amputation; however, none of our patients had limb loss, although the rate of graft thrombosis was 20.6%, treated with a second endovascular procedure. In a previous study comparing open surgery and endovascular treatment in a large series, there was no significant difference in the complication rates and 30- and 90-day mortality rates [29]. In recent years, endovascular treatment of PAA using multi-layer flow-modulating stents has been shown to be a safe and feasible method [30,31]. Nonetheless, there are some limitations to this study. Small sample size and nonrandomized, retrospective design are the main limitations. In addition, patients requiring emergency intervention due to acute limb ischemia were excluded from the study. Therefore, no results were obtained regarding the performance of the graft used in this patient group. There are also some prerequisites, such as diameter compliance, tortuosity, and angulation suitability that should not be required in the surgical treatment of popliteal artery aneurysms but should be provided in the treatment of endovascular stent grafts.

4. Conclusion
In conclusion, endovascular treatment of PAA using appropriate stent grafts is safe in selected cases who are at high risk for surgery due to comorbidities or those who refuse surgery. It is also advantageous owing to its shorter operation duration and length of hospital stay, more rapid functional recovery, minimal blood loss and wound site infection, and potential avoidance of general anesthesia. The distal vascular bed and distal and proximal attachment regions must be carefully examined before endovascular treatment. It is reasonable to avoid endovascular treatment due to an increased risk for thrombosis in patients with a low number of patent distal arteries or impaired distal flow. In addition, PAAs may present with concomitant AAA and patients should be evaluated for possible AAAs. Limb salvage is possible with a second endovascular intervention even in patients with graft thrombosis.
Acknowledgement/disclaimers/conflict of interest
The author(s) declared no financial support for the research and authorship; no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Informed consent
The necessary approval for our study has been granted by the Ordu Provincial Health Directorate on the date of July 6th, 2020 with the protocol no 0012038785.

References

1. Von Stumm M, Teufelsbauer H, Reichenspurner H, Debus ES. Two decades of endovascular repair of popliteal artery aneurysm. A meta-analysis. European Journal of Vascular and Endovascular Surgery 2015; 50: 351-359. doi: 10.1016/j.ejvs.2015.04.036

2. Kropman RH, De Vries JP, Moll FL. Surgical and endovascular treatment of atherosclerotic popliteal artery aneurysms. The Journal of Cardiovascular Surgery (Torino) 2007; 48: 2 81-288.

3. Rutherford RB. Arterial aneurysms. In: Cronenwett JL (editor). Rutherford’s Vascular Surgery. 6th ed. Philadelphia, PA, USA: Saunders; 2005. pp.1403-1408.

4. Dawson I, Sie RB, Van Bockel JH. Atherosclerotic popliteal aneurysm. The British Journal of Surgery 1997; 84: 293-299.

5. Kropman, R. H. J., Schrijver, A. M., Kelder, J. C., Moll, F . L., De Vries, J. P. P M Clinical outcome of acute leg ischemia due to thrombosed popliteal artery aneurysm: systematic review of 895 cases. European Journal of Vascular and Endovascular Surgery 2010; 39: 452-457. doi:10.1016/j.ejvs.2009.11.010

6. Wissgott C, Lüdtke CW, Vieweg H, Scheer F, Lichtenberg M et al. Endovascular treatment of aneurysms of the popliteal artery by a covered endoprosthesis. Clinical Medicine Insights. Cardiology 2014; 8(Suppl 2): 15-21. doi: 10.4137/CMC.S15232

7. Marin ML, Veith FJ, Panetta TF, Cynamon J, Bakal CW et al. Endovascular treatment of aneurysms of the popliteal artery by a covered endoprosthesis. Clinical Medicine Insights. Cardiology 2014; 8(Suppl 2): 15-21. doi: 10.4137/CMC.S15232

8. Wain RA, Hines G. A contemporary review of popliteal artery aneurysms. Cardiology in Review. 2007; 15 (2): 102-107. doi: 10.1097/01.crd.0000202012.52649.4a

9. Curi MA, Geraghty PJ, Merino OA, Veeraswamy RK, Rubin BG et al. Mid-term outcomes of endovascular popliteal artery aneurysm repair. Journal of Vascular Surgery. 2007; 45 (3): 505-510. doi:10.1016/j.jvs.2006.09.064

10. Gawenda M, Sorgatz S, Müller U, Walter M, Erasmi H. The thrombosed popliteal artery aneurysm and distal arterial occlusion: successful therapy by interdisciplinary management. The Thoracic and Cardiovascular Surgeon. 1995; 43: 112-126. doi: 10.1055/s-2007-1013782

11. Cross JE, Galland RB. Part one: for the motion asymptomatic popliteal artery aneurysms (less than 3 cm) should be treated conservatively. European Journal of Vascular and Endovascular Surgery. 2011; 41: 445-448. doi: 10.1016/j.ejvs.2011.02.007

12. Dawson J, Fitridge R. Update on aneurysm disease: current insights and controversies: peripheral aneurysms: when to intervene—is rupture really a danger? Progress in Cardiovascular Diseases. 2013; 56: 26-35. doi: 10.1016/j.pcad.2013.05.002

13. Whitehouse WM Jr, Wakefield TW, Graham LM, Kazmers A, Zelenock GB et al. Limb – threatening potential of arteriosclerotic popliteal artery aneurysms. Surgery. 1983; 93: 694-699.

14. Antonello M, Frigatti P, Battocchio P, Lepidi S, Cognolato D et al. Open repair versus endovascular treatment for asymptomatic popliteal artery aneurysm: results of a prospective randomized study. Journal of Vascular Surgery. 2005; 42: 185-193. doi: 10.1016/j.jvs.2005.04.049

15. Cervin A, Tjänström J, Ravn H, Acosta S, Hultgren R et al. Treatment of popliteal aneurysm by open and endovascular surgery a contemporary study of 592 procedures in Sweden. European Journal of Vascular and Endovascular Surgery. 2015; 50: 342-350. doi: 10.1016/j.ejvs.2015.03.026

16. Serrano Hernando FJ, Martinez López I, Hernández Mateo MM, Hernando Rydings M, Sánchez Hervás L et al. Comparison of popliteal artery aneurysm therapies. Journal of Vascular Surgery 2015; 61: 655-661. doi: 10.1016/j.jvs.2014.10.007

17. Nelson PR, Anthony Lee W. Endovascular treatment of popliteal artery aneurysms. Vascular. 2006; 14 (5): 297-304. doi: 10.2310/6670.2006.00049

18. Iedchik GM, Dougherty KG, Hernandez E, Mortazavi A, Strickman NE et al. Endovascular exclusion of popliteal artery aneurysms with stent-grafts: a prospective single-center experience. Journal of Endovascular Therapy 2009; 16: 215-223. doi: 10.1583/08-2412.1

19. Piazza M, Menegolo M, Ferrari A, Bonvini S, Hultgren R et al. Endovascular treatment of popliteal artery aneurysms: results of a prospective randomized study. Journal of Vascular Surgery. 2009; 50: 340-350. doi: 10.1016/j.jvs.2014.04.011

20. Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIUSTAR trial (Viabahn endoprosthesi with PRO-PATEN bioactive surface (VIA) versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). Journal of the American College of Cardiology 2013; 62: 1320-1327. doi: 10.1016/j.jacc.2013.05.079

1113
21. Siauw R, Koh EH, Walker SR. Endovascular repair of popliteal artery aneurysms: techniques, current evidence and recent experience. Australian and New Zealand Journal of Surgery 2006; 76: 505-511. doi: 10.1111/j.1445-2197.2006.03745.x

22. Garg, K., Rockman, C. B., Kim, B. J., Jacobowitz, G. R., Maldonado, T. S et al. Outcome of endovascular repair of popliteal artery aneurysm using the Viabahn endoprothesis. Journal of Vascular Surgery 2012; 55 (6): 1647-1653. doi: 10.1016/j.jvs.2011.12.059

23. Hernando, F. J. S., López, I. M., Mateo, M. M. H., Rydings, M. H., Hervás, L et al. Comparison of popliteal artery aneurysm therapies. Journal of Vascular Surgery 2015; 61: 655-661. doi: 10.1016/j.jvs.2014.10.007

24. Tielliu IF, Verhoeven EL, Zeebregts CJ, Prins TR, Span MM et al. Endovascular treatment of popliteal artery aneurysms: results of a prospective cohort study. Journal of Vascular Surgery 2005; 41: 561-567. doi: 10.1016/j.jvs.2004.12.055

25. Galland RB, Magee TR. Popliteal aneurysms: distortion and size related to symptoms. Journal of Vascular and Endovascular Surgery 2005; 30 (5): 534-538. doi: 10.1016/j.jvse.2005.05.021

26. Antonello M, Frigatti P, Battocchio P, Lepidi S, Dall'Antonia A et al. Endovascular treatment of asymptomatic popliteal aneurysm: 8-year concurrent comparison with open repair. The Journal of Cardiovascular Surgery (Torino) 2007; 48 (3): 267-274.

27. Midy D, Berard X, Ferdani M, Alric P, Brizzi V et al. A retrospective multicenter study of endovascular treatment of popliteal artery aneurysm. Journal of Vascular Surgery 2012; 51: 850-856. doi: 10.1016/j.jvs.2009.10.107

28. Stone PA, Jagannath P, Thompson SN, Campbell JE, Moussa AY et al. Evolving treatment of popliteal artery aneurysms. Journal of Vascular Surgery 2013; 57: 1306-1310. doi: 10.1016/j.jvs.2012.10.122

29. Galiñanes EL, Dombrovskiy VY, Graham AM, Vogel TR. Endovascular versus open repair of popliteal artery aneurysms: outcomes in the US Medicare population. European Journal of Vascular and Endovascular Surgery 2013; 47: 267-273. doi: 10.1177/1538574413475888

30. Ucci A, Curci R, Azzarone M, Bianchini Massoni C, Bozzani A et al. Early and mid-term results in the endovascular treatment of popliteal aneurysms with the multilayer flow modulator. Vascular 2018; 26 (5): 556-563. doi: 10.1177/1708538118771258

31. Elif Coşkun, Levent Altınay, Anıl Tekin, Ufuk Tütün. Endovascular treatment of popliteal artery aneurysms: A report of three cases. Turkish Journal of Vascular Surgery 2020; 29 (1): 59-62. doi: 10.9739/tjvs.2020.258